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Present therapies to minify hyperglycaemia and insulin resistance mainly target ATP-sensitive K+ channels (KATP) of pancreatic
cells and PPAR-γ to enhance the insulin secretion and potential for GLUT expression, respectively. These current approaches
are frequently associated with the various side eﬀects such as hypoglycaemia and cardiovascular adverse events. CDK5 is a
serine/threonine protein kinase, which forms active complexes with p35 or p39 found principally in neurons and in pancreatic
β cells. Pieces of evidence from recent studies recommend the vital role of CDK5 in physiological functions in nonneuronal cells
such as glucose-stimulated insulin secretion in pancreatic cells. Inhibition of CDK5 averts the decrease of insulin gene expression
through the inhibition of nuclear translocation of PDX-1 which is a transcription factor for the insulin gene. The present pieces
of evidence designate that CDK5 might be a potential drug target for the regulation of glucose-stimulated insulin secretion in the
treatment of diabetes mellitus.
1.Introduction
Cyclin-dependent kinases (CDKs) play essential roles in the
regulationofcelldivisioncycle[2].Cyclin-dependentkinases
(CDKs)representkeymoleculesinvolvedinregulationofthe
cellcycle.CDKs are serine/threonine kinases thatbecome ac-
tive only when associated with a regulatory partner (e.g.,
cyclins or other proteins). CDK/cyclin holoenzymes are acti-
vated by phosphorylation, which is catalyzed by CDK-acti-
vator kinase (CAK).
CDK5 is a serine-threonine kinase that is ubiquitously
expressedin mammaliantissues[3].Butthekinaseactivityis
limited in neurons because of the predominant expression of
its activators, p35 and p39, in neurons [3–6]. Recent studies
haveshownthatp35andp39areexpressedinpancreaticbeta
cells [7, 8] suggesting the possible activation and potential
role of CDK5 in insulin secretion.
Excellent recent researches have also documented the
high levels of CDK5 activity and p35 expression in both pan-
creatic beta cells and beta-cell-derived cell lines [9]. Studies
alsosuggestedthattwodiﬀerentpathwaysaremainlyrespon-
sible for stimulating insulin secretion: a triggering pathway,
in which depolarization by closure of the K+ATP channel
directly activates L-VDCC and results in the rise of cytosolic
Ca2+, and an augmentative pathway, in which cAMP is an
important mediator [10].
The regulation of CDK5 kinase activity is somewhat dif-
ferent from that of other CDKs. It is well established that
phosphorylation of Thr160 within CDK2 by CAK and
dephosphorylation of Tyr15 by cdc25 are necessary for the
maximum activation [11, 12]. Although there are contra-
dictory results regarding the eﬀect of tyrosine phosphory-
lation on CDK5 activity, it seems that tyrosine-dependent
regulation is signiﬁcant for CDK5 [13, 14]. At present, it
is generally thought that binding of p35 or p39 to CDK5
is both necessary and suﬃcient to activate CDK5 kinase.
Type 2 diabetes is characterized by a deﬁcit in b-cell mass
with increased beta-cell apoptosis as well as a deﬁcit in b-cell
function [15].2 International Journal of Endocrinology
Table 1: IC50 (nM/μM) of various CDK5 inhibitors.
Compound no. Compound Chemical name IC50
CDK5/p25
1
N
N N
N
N
HO
NH
H
Olomoucine
2-[[9-Methyl-6-
[(phenylmethyl)amino]-9H-purin-
2-yl]amino]-ethanol
3μM
2
N
N
N
N
N
HO
NH
H
Roscovitine
2-(6-Benzylamino)-9-isopropyl-
9H-purin-2-ylamino)butane-1-ol 0.2μM
3
N N
N
NH
S
S
Me
H3COCHN
N-(5-(6,7-Diphenyl-5H-
[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazin-3-yl)-4-
methylthiophen-2-yl)acetamide
44 ± 2nM
4
N N
N
NH
S
S
Me
Cl2HCOCHN
2,2-Dichloro-N-(5-(6,7-Diphenyl-
5H-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazin-3-yl)-4-
methylthiophen-2-yl)
acetamide
72 ± 2nMInternational Journal of Endocrinology 3
Table 1: Continued.
Compound no. Compound Chemical name IC50
CDK5/p25
5
N N
N
N
S
S
H3C
H3COCHN
N-(4-Methyl-5-(6-phenyl-
[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazol-3-yl)thiophen-
2-yl)acetamide
42 ± 1nM
6
N N
N
N
S
S
H3C
Cl2HCOCHN
2,2-Dichloro-N-(4-methyl-5-(6-
phenyl-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazol-3-yl)thiophen-
2-yl)acetamide
30 ± 1nM
7
N
N
HO
NH
O
2-(4-(Benzylamino)-1-isopropyl-
1H-benzo[d]imidazol-6-
yloxy)butan-1-ol
13μM
8
N
N N
N
S
NHCOC6H5
SCH2CONHN=CHC6H5
H3COCHN
N-(3-((2-Acetamidothiazol-4-
yl)methyl)-5-(2-(2-
benzylidenehydrazinyl)-2-
oxoethylthio)-4H-1,2,4-triazol-4-
yl)benzamide
048 ±
02nM4 International Journal of Endocrinology
Table 1: Continued.
Compound no. Compound Chemical name IC50
CDK5/p25
9
N
N
N
NH
F
H
H H
H
H
C
1-((1H-Imidazol-5-yl)methyl)-7-
ﬂuoro-9H-pyrido[3,4-b]indole 05μM
10
N
N
N
N
N
N
S
S
H3C
NHCOCH3
H
34 ± 1nM
Neurons in Alzheimer’s disease and β-cells in type 2 di-
abetes are characterized by endoplasmic reticulum (ER)
stress-induced apoptosis associated with formation of mis-
folded toxic oligomers of locally expressed amyloidogenic
proteins (Alzheimer’s b-protein [IAbP] in brain and islet
amyloid polypeptide [IAPP] in beta-cells) [16, 17].
2. Cyclin-DependentKinase5andGlucotoxicity
Glucose enhances p35 gene expression, promoting the for-
mation of active p35/CDK5 complexes that in turn regulate
the expression of the insulin gene [7]. Transient elevations of
extracellular glucose promote pancreatic beta-cell function
andsurvival[3,4]whereaschronicelevationsofglucosehave
the opposite eﬀect, impairing beta-cell function and survival
[18–20]. The deleterious eﬀects of chronically elevated
glucose are referred to as glucotoxicity.
The suppression of insulin gene expression by glucotoxi-
cityinbetacellsinvolvesseveraltranscriptionfactorsanddif-
ferent pathophysiological mechanisms. These mechanisms
include the translocation of PDX-1 (also known as STF-1,
IPF-1, and IDX-1) from the nucleus to the cytoplasm [21].
There are pieces of evidence which strongly suggest that
overstimulation of CDK5 is involved in the cytoplasmic
translocation of PDX-1 during glucotoxicity. Recent works
indicates that elevation of CDK5 activity is due to an
increased expression level of its p35 activator without
changes in the level of CDK5 protein. The overall eﬀects
of increased activity of CDK5 are decreased rates of insulin
release, reduced insulin production and diminished insulin
gene expression (see Figure 1)[ 22, 23].
3. Regulation of InsulinRelease by CDK5
Similar to other cyclin-dependent kinases, CDK5 too needs
cyclinproteinstoactivatethekinaseactivity,whichhavebeen
recognized as p35 and its isoform p39 (see Figure 2)[ 3–5].
It has been shown that CDK5 is associated with exocyto-
sis machinery and is also involved in the neurotransmitter
release. As the neuron and pancreatic β-cell allocated to
the same secretion mechanism, it is obvious to understand
that CDK5 would adjust the insulin secretion in pancreatic
β cells. Insulin secretion is about to begin when calcium
is inﬂuxed through the L-VDCC in reaction to enhancedInternational Journal of Endocrinology 5
Glucose
Glucose
transporter
Cdk 5
PDX-1 PDX-1
Nucleus
CCAAT
enhancer binding Gene
expression
Tyrosine
kinase
receptor
Insulin
Endoplasmic
reticulum
Golgi apparatus
Pancreatic β cell
protein-β
Figure 1: Regulation of pancreatic β-cell function by Cyclin-
Dependent Kinase 5 (CDK5). Cyclin-Dependent Kinase 5 (CDK5)
is overactivated by high glucose or by signal downstream of
tyrosine kinase receptor. The PDX 1 is translocated from nucleus
to cytoplasm due to activation of CDK5. That results in the
suppressionofgeneexpressionbyinductionoftranscriptionfactors
such as CCAAT enhancer binding protein β, which acts as negative
regulator of insulin gene transcription.
level of extracellular glucose. CDK5 phosphorylates loop II-
III of the α1c subunit of L-VDCC and restrains the channel
activity that ultimately results in the inhibition of glucose-
stimulated insulin secretion.
4. Role of CDK5 in Regulation of
PPAR-γ Activity
ARecentstudyclearlydemonstratedthatCDK5regulatesthe
PPAR-γ activity in the pancreatic β cells [1]. In their ﬁnd-
ings they make obvious that the enzyme cyclin-dependent
kinase 5 (CDK5) phosphorylates PPARγ on serine residue
273. Activation of CDK5 itself involves truncation of the
p35 protein to p25, possibly in response to cytokines or
other proinﬂammatory signals p25 then translocates to the
nucleus, where it associates with, and activates, CDK5 in
a way that is evocative of the activation of other CDK en-
zymes. Phosphorylation of CDK5 causes the alteration and
inhibition of speciﬁc antiobesity target genes (Figure 3)[ 1].
Enigmatically, the antidiabetic PPARγ ligands that were
previously considered to act solely by activating PPARγ
potently inhibit its CDK5-mediated phosphorylation [1],
probably by inducing a conformational change in PPARγ.
The data from the above study demonstrates that
antidiabetic PPARγ ligands inhibit CDK5 phosphorylation
of PPARγ in vivo and reverse changes in gene expression
linked to this modiﬁcation. Treatment with roscovitine, a
CDK5 inhibitor, signiﬁcantly suppressed CDK5-mediated
phosphorylation and most of the gene set regulated by the
Loop II
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Ca2+
α1c subunit
P
Cdk5
Insulin
Unable to fuse
Golgi
Pancreatic β-cell
L-VDCC
Figure 2: Regulation of insulin secretion by CDK5: cyclin-
dependent kinase 5 (CDK5) prevents the secretion of insulin by
phosphorylating the loop II and loop III of α1c subunit of L-type
voltage-dependent calcium channels (L-VDCCs) so that calcium
could not ﬁnd the entry into the pancreatic β cell as the L-VDCC
channel activity is deterred due to the phosphorylation leading to
the decreased concentration of cytosolic Ca2+.
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Figure 3: Choi et al. [1] show that PPARγ activity is controlled
by the CDK5. Obesity leads to the various signals that cause
the cleavage of p35 to p25 which will then translocates to the
nucleus and forms a bond with CDK5 and activates it. CDK5
phosphorylates the PPARγ receptor on serine residue 273 averts
the transcription of antiobesity eﬀects, while the full activation of
PPARγ by PPARγ agonists may probably responsible for the weight
gain and Fluid retention.6 International Journal of Endocrinology
Compound 3
Active site on CDK5 receptor
Figure 4: The docked conformation of compound 3 with the
receptor CDK5/p25 (PDB: 3O0G). Compound 3 is indicated by red
color while the most active site of the CDK5 receptor is shown with
green color.
Compound 4
Active site on CDK5 receptor
Figure 5: The docked conformation of compound 4 with the
receptor CDK5/p25 (PDB: 3O0G). Compound 4 is indicated by red
color while the most active site of the CDK5 receptor is shown with
green color.
phosphorylation of PPARγ. It is important in the research
study that the therapeutic doses used in animals did not lead
to a complete inhibition of the CDK5 phosphorylation of
PPARγ. It is clear from the vital research that CDK5 plays an
important role in adipogenic diabetes and the inhibition of
CDK5-mediated phosphorylation of PPARγ receptor could
lead to the improvement in the serious side eﬀects associated
with the PPARγ agonists which may occur through their
classical agonist actions. Therefore, the full PPARγ ligands
activate the PPARγ receptor which could be the reason for
weight gain and ﬂuid retention. We need to more robust
therapy which could only target the phosphorylation of
PPARγ.
5.CDK5InhibitorsasPotential
Therapeutic Target
Cyclin-dependent kinases (CDKs) play indispensable roles
in the regulation of cell division cycle [24]. There are many
pieces of evidence which have shown the importance of
CDKs in the diabetes [1]. The initial search for CDK inhib-
itors was commenced because of their antitumor potential
and was mostly based on the use of CDK1/cyclin B as a mo-
Compound 5
Active site of Cdk5 receptor
Figure 6: The docked conformation of compound 5 with the
receptor CDK5/p25 (PDB: 3O0G). Compound 5 is indicated by red
color while the most active site of the CDK5 receptor is shown with
purple color.
Compound 6
Active site of Cdk5 receptor
Figure 7: The docked conformation of compound 6 with the
receptor CDK5/p25 (PDB: 3O0G). Compound 6 is indicated by red
color while the most active site of the CDK5 receptor is shown with
green color.
lecular target. Frequent deregulations of CDK in cancers
provided the main thrust to the vigorous rummage around
for pharmacological inhibitors of these kinases.
CDK5 is a serine/threonine kinase ubiquitously express-
ed in the mammalian tissues, with best characterized func-
tional role in the Alzheimer’s disease [25]. Although the ori-
gin of pancreatic endocrine cells is endodermal but it shares
many molecular and cellular characteristics with neural
ectoderm-derived neurons. Because of the similarities be-
tween neurons and pancreatic β cells and between the neural
degeneration of Alzheimer’s disease and the deterioration of
pancreatic β-cell functioning, CDK5 plays an important role
in the pathogenesis of diabetes mellitus [7]. It is now clear
that phosphorylation of serine and threonine residues plays
a fundamental role in pathogenesis of adipogenic diabetes
and constitutes a major pharmacological target [1]. CDK5
has triﬂing enzymatic activity and necessitates association
with regulatory proteins for comprehensive activation. Two
noncyclic proteins, p35 and p39, have been discovered as
CDK5 activators that are restricted in the cell membrane.
Frequent deregulations of CDKs in cancer [26]p r o v i d e d
the main drive to the active search for pharmacological
inhibitors of CDK5. The ﬁrst pharmacological CDK inhib-
itors (6-dimethylaminopurine andisopentenyladenine) were
neither active nor selective. However the discovery paved the
way for the synthesis of many other CDK inhibitors andInternational Journal of Endocrinology 7
Compound 7
Active site of CDK5 receptor
Figure 8: The docked conformation of compound 7 with the
receptor CDK5/p25 (PDB: 3O0G). Compound 7 is indicated by red
color while the most active site of the CDK5 receptor is shown with
yellow color.
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proved to be the starting point for further research. More
than 50 inhibitors for CDKs have now been reported.
Despite signiﬁcant chemical assortment, all CDK inhib-
itors share some common properties: (1) they are ﬂat, (2)
they combine mostly by hydrophobic interactions, (3) they
compete with ATP for binding, (4) they have low molecular
weights.
Hitherto two types of CDK5 inhibitor, chemical com-
pounds, and peptides have been acknowledged. The most
recurrently utilized chemical compounds are purine ana-
logues such as Roscovitine and Olomoucine. These inhib-
itors compete with ATP for binding to CDK5 and form
hydrogenbondswithCDK5.Howeverduetohighhomology
of the primary amino acid sequence and the 3D structure of
CDK5 and other CDKs, particularly in the kinase domain,
roscovitine and olomoucine can also inhibit other CDKs to
some extent (see Schemes 1 and 2).
To surmount this problem, CDK5 inhibitory peptides
have been discovered. These peptides are obtained from an
explicit region in p35 protein and are highly speciﬁc for
CDK5. Studies using such CDK5 inhibitory peptides suggest
that these peptides could prevent CDK5-mediated cell death.
However, the IC50s of these peptides are higher and the
membrane permeability of these peptides is lower than those
of roscovitine and olomoucine.
6.NovelCDK5/p25 Inhibitors
Recently there were comprehensive researches done to target
speciﬁcallytheCDK5/p25.Researchershavefoundarangeof
compounds with high potency. Some of them are described
here with IC50 in nM (see Table 1).
7. Docking Studiesof Some Novel CDK5
Inhibitors
In order to understand the structural requirements of the
inhibitors with respect to their bioactivity proﬁle enhance-
ments against cyclin-dependent kinase 5/p25 (CDK5/p25),
molecular docking with Discovery Studio Client v2.5.0.9164
(Accelrys) was carried out.
As from the docking with Discovery Studio 2.5 it
is obvious that the most potent inhibitor of CDK5/p25
receptor as compared to the standard compounds, namely,
Olomoucine and Roscovitine, is compound no. 6. The
binding pattern of compound 6 is quite diﬀerent from the
other entire compounds, and it integrates tightly with the
receptor in order to inhibit it (see Figures 4, 5, 6, 7, 8, 9, 10,
11, 12, 13).
8. Discussion and Conclusion
From the recent ﬁndings it has been suggested that CDK5
is an imperative contrivance which might prove to be a
signiﬁcant target for take care of type 2 diabetes mellitus.
It has been shown from previous research study [7] that
expression of p35 and the protein kinase activity of the
p35/CDK5complexinβ cellsaretightlyregulatedbychanges8 International Journal of Endocrinology
Compound 8
Active site of Cdk5 receptor
Figure 9: The docked conformation of compound 8 with the
receptor CDK5/p25 (PDB: 3O0G). The compound 8 is indicated by
red color while the most active site of the CDK5 receptor is shown
with yellow color.
Active site of Cdk5 receptor
Compound 10
Figure 10: The docked conformation of compound 10 with the
receptor CDK5/p25 (PDB: 3O0G). Compound 10 is indicated by
red color while the most active site of the CDK5 receptor is shown
with yellow color.
Compound 11
Active site of Cdk5 receptor
Figure 11: The docked conformation of compound 11 with the
receptor CDK5/p25 (PDB: 3O0G). Compound 11 is indicated by
red color while the most active site of the CDK5 receptor is shown
with yellow color.
Olomoucine
A c t i v es i t eo nC d k 5r e c e p t o r
Figure 12: The docked conformation of Olomoucine with the
receptor CDK5/p25 (PDB: 3O0G). The Olomoucine is indicated by
red color while the most active site of the CDK5 receptor is shown
with yellow color.
Roscovitine
Active site on Cdk5 receptor
Figure 13: The docked conformation of Roscovitine with the
receptor CDK5/p25 (PDB: 3O0G). The Roscovitine is indicated by
red color while the most active site of the CDK5 receptor is shown
with green color.
in the extracellular concentration of glucose. It is known that
the expression of genes essential for the function of β cells,
suchasinsulin,PDX-1(pancreaticandduodenalhomeobox-
1), amylin, and glucose transporter 2, is closely regulated
by extracellular concentrations of glucose. This circumstance
suggeststhatthep35/CDK5 proteinkinasepathwaymayplay
an important role in β-cell function. Further it is apparent
that inhibition of CDK5 under conditions of glucotoxicity
preserves insulin gene expression by a mechanism that
involves the restoration of the DNA binding and nuclear
localization of PDX-1 and restoration of the nuclear levels
of PDX-1 by inhibition of CDK5 occurs by preventing the
translocation of PDX-1 from the nucleus to the cytoplasm
[22].
It has been a long time since CDK5 was discovered.
All-embracing studies have been conducted to elucidate the
function of CDK5. Physiologically, CDK5 has been impli-
catedintheregulationofneuronaldevelopmentandsynaptic
transduction. Pathogenically, CDK5 has been accepted as
a critical arbitrator in various neurodegenerative diseases,
including Alzheimer’s disease. Above and beyond the neu-
ronal functions of CDK5, latest studies also advocate that
CDK5 might regulate insulin secretion in pancreatic β
cells.
CDK5 is all over the place expressed, with high levels
of expression in the central nervous system. It is multi-
functional with predictable roles in signalling pathways and
genetranscription,organisationofthecytoskeletonandfocal
adhesions, membrane dynamics, and function as well as cell
metabolism [27]. More explicitly, in addition to its positive
role in insulin secretion [9], CDK5 is also required for
insulin-stimulated glucose uptake, upsetting translocation
of GLUT4 [28, 29]. Therefore, aiming CDK5 to improve
PPAR-γ activity and metabolic control is not without chal-
lenges. A more eye-catching approach is to coalesce this
new consideration with our mushrooming admiration of
the prospective selectivity and eﬃcacy aﬀorded by the
CDK5/p25 inhibitors to endow with less adverse eﬀects of
Thiazolidinediones (TZDs). On the basis of these ﬁndings,
it is obvious that CDK5 might be a constructive target for
the treatment of diabetes. On the whole, several scientistsInternational Journal of Endocrinology 9
and Choi and colleagues’ work heralds a new epoch of
drug discovery, in which PPARγ activity could be ratio-
nally targeted to ameliorate diabetes and circumvent side
eﬀects.
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